Sign In
Buy VVOS
Vivos Therapeutics Earnings Calls
| Release date | May 20, 2026 |
| EPS estimate | -$0.450 |
| EPS actual | -$0.520 |
| EPS Surprise | -15.56% |
| Revenue estimate | 4.349M |
| Revenue actual | 5.141M |
| Revenue Surprise | 18.22% |
| Release date | Apr 15, 2026 |
| EPS estimate | -$0.495 |
| EPS actual | -$0.580 |
| EPS Surprise | -17.17% |
| Revenue estimate | 7.097M |
| Revenue actual | 3.823M |
| Revenue Surprise | -46.13% |
| Release date | Nov 19, 2025 |
| EPS estimate | -$0.530 |
| EPS actual | -$0.490 |
| EPS Surprise | 7.55% |
| Revenue estimate | 7.097M |
| Revenue actual | 6.783M |
| Revenue Surprise | -4.42% |
| Release date | Aug 19, 2025 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.550 |
| EPS Surprise | -103.70% |
| Revenue estimate | 3.653M |
| Revenue actual | 3.82M |
| Revenue Surprise | 4.56% |
Last 4 Quarters for Vivos Therapeutics
Below you can see how VVOS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 19, 2025 |
| Price on release | $4.27 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.550 |
| EPS surprise | -103.70% |
| Date | Price |
|---|---|
| Aug 13, 2025 | $4.61 |
| Aug 14, 2025 | $4.61 |
| Aug 15, 2025 | $4.11 |
| Aug 18, 2025 | $4.45 |
| Aug 19, 2025 | $4.27 |
| Aug 20, 2025 | $4.13 |
| Aug 21, 2025 | $4.60 |
| Aug 22, 2025 | $4.20 |
| Aug 25, 2025 | $4.63 |
| 4 days before | -7.38% |
| 4 days after | 8.31% |
| On release day | -3.28% |
| Change in period | 0.325% |
| Release date | Nov 19, 2025 |
| Price on release | $2.36 |
| EPS estimate | -$0.530 |
| EPS actual | -$0.490 |
| EPS surprise | 7.55% |
| Date | Price |
|---|---|
| Nov 13, 2025 | $2.42 |
| Nov 14, 2025 | $2.34 |
| Nov 17, 2025 | $2.39 |
| Nov 18, 2025 | $2.47 |
| Nov 19, 2025 | $2.36 |
| Nov 20, 2025 | $2.12 |
| Nov 21, 2025 | $2.20 |
| Nov 24, 2025 | $2.15 |
| Nov 25, 2025 | $2.20 |
| 4 days before | -2.48% |
| 4 days after | -6.78% |
| On release day | -10.17% |
| Change in period | -9.09% |
| Release date | Apr 15, 2026 |
| Price on release | $1.47 |
| EPS estimate | -$0.495 |
| EPS actual | -$0.580 |
| EPS surprise | -17.17% |
| Date | Price |
|---|---|
| Apr 09, 2026 | $1.16 |
| Apr 10, 2026 | $1.21 |
| Apr 13, 2026 | $1.22 |
| Apr 14, 2026 | $1.35 |
| Apr 15, 2026 | $1.47 |
| Apr 16, 2026 | $1.09 |
| Apr 17, 2026 | $0.97 |
| Apr 20, 2026 | $1.01 |
| Apr 21, 2026 | $1.03 |
| 4 days before | 26.72% |
| 4 days after | -29.93% |
| On release day | -25.85% |
| Change in period | -11.21% |
| Release date | May 20, 2026 |
| Price on release | $0.590 |
| EPS estimate | -$0.450 |
| EPS actual | -$0.520 |
| EPS surprise | -15.56% |
| Date | Price |
|---|---|
| May 14, 2026 | $0.690 |
| May 15, 2026 | $0.641 |
| May 18, 2026 | $0.599 |
| May 19, 2026 | $0.585 |
| May 20, 2026 | $0.590 |
| May 21, 2026 | $0.585 |
| May 22, 2026 | $0.610 |
| May 26, 2026 | $0.647 |
| May 27, 2026 | $0.661 |
| 4 days before | -14.49% |
| 4 days after | 12.05% |
| On release day | -0.88% |
| Change in period | -4.19% |
Vivos Therapeutics Earnings Call Transcript Summary of Q1 2026
Vivos reported Q1 2026 revenue of $5.1M, a 70% year-over-year increase and 34% sequential growth driven primarily by the June 2025 acquisition of Sleep Center of Nevada (SCN) and expansion of diagnostic and OSA treatment services. Completed patient appointments rose sharply (Visit 2s and other KPIs improved), with strong growth in myofunctional therapy and other clinical procedures. Gross profit grew to $3.1M and gross margin expanded to 60% (from 50% a year earlier), reflecting the higher-margin nature of the new model. Cost of sales and G&A increased due to SCN operating costs, added staff, nonrecurring professional fees, and higher depreciation. Cash used in operations was ~$6M for the quarter; cash on hand was ~$2.1M as of March 31, 2026, and total liabilities were ~$26.3M. Management is implementing cost savings, exploring debt restructuring and equity measures, and expects to need additional financing to meet near- and longer-term cash needs and NASDAQ equity requirements. Management reiterated confidence in the pivot to an integrated sleep center model, highlighted initiatives to affiliate with medical specialty groups (e.g., cardiology), expand insomnia services and pediatric programs (high margin), and said they expect margins to ramp toward target levels by year-end as provider experience and payer coverage increase.
